Carlsmed (NASDAQ:CARL) Posts Quarterly Earnings Results

Carlsmed (NASDAQ:CARL) posted its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05, Zacks reports. Carlsmed updated its FY 2025 guidance to EPS.

Carlsmed Stock Down 1.7%

Carlsmed stock traded down $0.21 during midday trading on Thursday, hitting $11.89. 35,399 shares of the company’s stock were exchanged, compared to its average volume of 134,172. Carlsmed has a 52-week low of $11.76 and a 52-week high of $16.20. The stock’s 50-day moving average price is $13.59.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings initiated coverage on Carlsmed in a research report on Thursday, October 16th. They issued a “sell (e)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Carlsmed presently has an average rating of “Sell”.

Hedge Funds Weigh In On Carlsmed

An institutional investor recently bought a new position in Carlsmed stock. Rhumbline Advisers bought a new position in shares of Carlsmed, Inc. (NASDAQ:CARL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,903 shares of the company’s stock, valued at approximately $79,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).